PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT

Haocheng BAI; Jing FENG; Sanbin WANG

doi:10.16016/j.1000-5404.202006155

您当前的位置：

首页 >

文章列表页 >

PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT

更新时间：2026-01-09

- PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT
- Journal of Third Military Medical University Vol. 42, Issue 17, Pages: 1712-1716(2020)
- 作者机构：
- 作者简介：
- 基金信息：
  
  the Key Special Project of National Key R & D Program(2017YFA0105502)
- DOI：10.16016/j.1000-5404.202006155
  CLC：
- Received：17 June 2020，
  
  Published：15 September 2020
- 稿件说明：
移动端阅览
Haocheng BAI, Jing FENG, Sanbin WANG. PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT[J]. Journal of Third Military Medical University, 2020, 42(17): 1712-1716.
DOI：

Haocheng BAI, Jing FENG, Sanbin WANG. PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT[J]. Journal of Third Military Medical University, 2020, 42(17): 1712-1716. DOI： 10.16016/j.1000-5404.202006155.

摘要

Abstract

Objective

To evaluate the efficacy of post-transplant cyclophosphamide (PT-Cy) combined with ruxolitinib and tocilizumab in the prevention of acute graft versus host disease (aGVHD) after haploidentical allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) by a single-arm prospective study.

Methods

A total of 56 patients undergoing haploidentical allogeneic peripheral blood HSCT in our department from January 1

2019 to March 1

2020 were recruited in this study. The GHVD prevention regiments included: cyclophosphamide 40 mg/kg×2 d (+3～+4 d)

ciclosporin 2 mg/kg (+5～+180 d) and mycophenolate sodium enteric-coated tablets 10 mg/kg (+5～+35 d)

tocilizumab 8 mg/kg×1 d (-1 d)

and ruxolitinib (-1～+180 d). The effect of transplantation and adverse effect of aGVHD were observed.

Results

The implantation of stem cells was completed successfully among all the 56 patients (100%)

with an implantation time of neutrophils of 13 d and of platelets of 17 d. The incidence of grade Ⅱ～Ⅳ aGVHD was 23.2%

and that of grade Ⅲ～Ⅳ was 12.5%. One patient died due to poor control of aGVHD

6 patients had pulmonary infection; 12 patients had human cytomegalovirus infection or persistent viral copy number rise; 8 patients had Epstein-Barr virus infection or persistent viral copy number rise; and 8 patients had hematopoietic suppression. During the follow-up of 2～16 months (median 8 months)

nonrelapse mortality (NRM) was 7.2%

and overall survival rate (OS) was 91.4%.

Conclusion

;PT-Cy combined with ruxolitinib and tocilizumab regimen can effectively prevent aGVHD for haplotype concomitant transplantation patients. No significant increases of bacterial and viral infections are observed. This program has a higher incidence of hematopoietic suppression and a good overall tolerance.

关键词

Keywords

references

黄小丽刘林袁忠涛芦可替尼对慢性移植物抗宿主病患者的疗效及安全性研究第三军医大学学报 2019 41 23 2290 2295 10.16016/j.1000-5404.201906230. 黄小丽, 刘林, 袁忠涛, 等. 芦可替尼对慢性移植物抗宿主病患者的疗效及安全性研究[J].第三军医大学学报,2019,41(23):2290-2295. DOI:10.16016/j.1000-5404.201906230.

HUANG X L LIU L YUAN Z T Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease J Third Mili Med Univ 2019 41 23 2290 2295 10.1182/asheducation-2018.1.228 HUANG X L, LIU L, YUAN Z T, et al . Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease[J ] . J Third Mili Med Univ, 2019, 41(23): 2290-2295. DOI:10.16016/j.1000-5404.201906230.

HAMILTON B K Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation Hematol Am Soc Hematol Educ Program 2018 2018 1 228 235 HAMILTON B K. Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation[J]. Hematol Am Soc Hematol Educ Program, 2018, 2018(1): 228-235. DOI:10.1182/asheducation-2018.1.228.

王顺清 HLA单倍体相合造血干细胞移植研究进展实用医学杂志 2016 32 10 1553 1555 王顺清. HLA单倍体相合造血干细胞移植研究进展[J]. 实用医学杂志, 2016, 32(10): 1553-1555.

WANG S Q Research progress of HLA haploid compatible hematopoietic stem cell transplantation J Pract Med 2016 32 10 1553 1555 10.1371/journal.pone.0109799 WANG S Q. Research progress of HLA haploid compatible hematopoietic stem cell transplantation[J]. J Pract Med, 2016, 32(10): 1553-1555.

BASHEY A ZHANG M J MCCURDY S R Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide J Clin Oncol 2017 35 26 3002 3009 10.1200/JCO.2017.72.8428. BASHEY A, ZHANG M J, MCCURDY S R, et al . Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide[J ] . J Clin Oncol, 2017, 35(26): 3002-3009. DOI:10.1200/JCO.2017.72.8428.

CHOI J COOPER M L ALAHMARI B Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect PLoS ONE 2014 9 10 10.1371/journal.pone.0109799. CHOI J, COOPER M L, ALAHMARI B, et al . Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect[J ] . PLoS ONE, 2014, 9(10): e109799. DOI:10.1371/journal.pone.0109799.

GERGIS U VAN BESIEN K Tocilizumab, in search for a role in acute GVHD Leuk Lymphoma 2019 60 9 2101 2103 10.1080/10428194.2019.1613545. GERGIS U, VAN BESIEN K. Tocilizumab, in search for a role in acute GVHD[J]. Leuk Lymphoma, 2019, 60(9): 2101-2103. DOI:10.1080/10428194.2019.1613545.

李岩徐雪松孙志血液病整合诊断在医学检验住院医师规范化培训中的应用与探讨中国实验诊断学 2018 22 10 1867 1868 李岩, 徐雪松, 孙志. 血液病整合诊断在医学检验住院医师规范化培训中的应用与探讨[J].中国实验诊断学,2018,22(10):1867-1868.

LI Y XU X S SUN Z Application and discussion of integrated diagnosis of hematological diseases in standardized training of medical laboratory residents Chin J Lab Diagn 2018 22 10 1867 1868 LI Y, XU X S, SUN Z. Application and discussion of integrated diagnosis of hematological diseases in standardized training of medical laboratory residents[J].Chin J Lab Diagn, 2018,22(10):1867-1868.

HARRIS A C YOUNG R DEVINE S International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD international consortium Biol Blood Marrow Transplant 2016 22 1 4 10 10.1016/j.bbmt.2015.09.001. HARRIS A C, YOUNG R, DEVINE S, et al . International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD international consortium[J ] . Biol Blood Marrow Transplant, 2016, 22(1): 4-10. DOI:10.1016/j.bbmt.2015.09.001.

XU L P CHEN H CHEN J The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China: recommendations from the Chinese Society of Hematology J Hematol Oncol 2018 11 1 1 17 10.1186/s13045-018-0564-x. XU L P, CHEN H, CHEN J, et al . The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China: recommendations from the Chinese Society of Hematology[J ] . J Hematol Oncol, 2018, 11(1): 1-17. DOI:10.1186/s13045-018-0564-x.

WANG Y CHANG Y J CHEN L Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes OncoImmunology 2017 6 11 10.1080/2162402x.2017.1356152. WANG Y, CHANG Y J, CHEN L, et al . Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes[J ] . OncoImmunology, 2017, 6(11): e1356152. DOI:10.1080/2162402x.2017.1356152.

SCHROEDER M A CHOI J STASER K The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia Biol Blood Marrow Transplant 2018 24 6 1125 1134 10.1016/j.bbmt.2017.12.797. SCHROEDER M A, CHOI J, STASER K, et al . The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia[J ] . Biol Blood Marrow Transplant, 2018, 24(6): 1125-1134. DOI:10.1016/j.bbmt.2017.12.797.

ELLI E M BARAT C MENDICINO F Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib Front Oncol 2019 9 1186 10.3389/fonc.2019.01186. ELLI E M, BARAT C, MENDICINO F, et al . Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib[J ] . Front Oncol, 2019, 9: 1186. DOI:10.3389/fonc.2019.01186.

BETTS B C ABDEL-WAHAB O CURRAN S A Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen Blood 2011 118 19 5330 5339 10.1182/blood-2011-06-363408. ETTS B C, ABDEL-WAHAB O, CURRAN S A, et al . Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen[J ] . Blood, 2011, 118(19): 5330-5339. DOI:10.1182/blood-2011-06-363408.

SPOERL S MATHEW N R BSCHEIDER M Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease Blood 2014 123 24 3832 3842 10.1182/blood-2013-12-543736. SPOERL S, MATHEW N R, BSCHEIDER M, et al . Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease[J ] . Blood, 2014, 123(24): 3832-3842. DOI:10.1182/blood-2013-12-543736.

MOROZOVA E V BARABANSHIKOVA M V MOISEEV I S A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis Acta Haematol 2020 1 8 10.1159/000506758. MOROZOVA E V, BARABANSHIKOVA M V, MOISEEV I S, et al . A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis[J ] . Acta Haematol, 2020: 1-8. . DOI:10.1159/000506758.

KENNEDY G A VARELIAS A VUCKOVIC S Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial Lancet Oncol 2014 15 13 1451 1459 10.1016/S1470-2045(14)71017-4. KENNEDY G A, VARELIAS A, VUCKOVIC S, et al . Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial[J ] . Lancet Oncol, 2014, 15(13): 1451-1459. DOI:10.1016/S1470-2045(14)71017-4.

SOLTERMANN Y HEIM D MEDINGER M Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study Ann Hematol 2019 98 6 1485 1493 10.1007/s00277-019-03673-3. SOLTERMANN Y, HEIM D, MEDINGER M, et al . Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study[J ] . Ann Hematol, 2019, 98(6): 1485-1493. DOI:10.1007/s00277-019-03673-3.

LUZNIK L JALLA S ENGSTROM L W Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide Blood 2001 98 12 3456 3464 10.1182/blood.v98.12.3456. LUZNIK L, JALLA S, ENGSTROM L W, et al . Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide[J ] . Blood, 2001, 98(12): 3456-3464. DOI: 10.1182/blood.v98.12.3456.

RIEGER C T RIEGER H KOLB H J Infectious complications after allogeneic stem cell transplantation: incidence in matched-related and matched-unrelated transplant settings Transpl Infect Dis 2009 11 3 220 226 10.1111/j.1399-3062.2009.00379.x. RIEGER C T, RIEGER H, KOLB H J, et al . Infectious complications after allogeneic stem cell transplantation: incidence in matched-related and matched-unrelated transplant settings[J ] . Transpl Infect Dis, 2009, 11(3): 220-226. DOI:10.1111/j.1399-3062.2009.00379.x.

RAIOLA A M DOMINIETTO A GHISO A Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning Biol Blood Marrow Transplant 2013 19 1 117 122 10.1016/j.bbmt.2012.08.014. RAIOLA A M, DOMINIETTO A, GHISO A, et al . Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning[J ] . Biol Blood Marrow Transplant, 2013, 19(1): 117-12 2. DOI:10.1016/j.bbmt.2012.08.014.

FAYARD A DAGUENET E BLAISE D Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) Bone Marrow Transplant 2019 54 10 1586 1594 10.1038/s41409-019-0475-7. FAYARD A, DAGUENET E, BLAISE D, et al . Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)[J ] . Bone Marrow Transplant, 2019, 54(10): 1586-1594. DOI:10.1038/s41409-019-0475-7.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect and mechanism of human umbilical cord mesenchymal stem cells on preventing murine acute graft-versus-host disease

Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease

Related Author

Weihao WANG

Xi ZHANG

Shijie YANG

Qiangguo GAO

Yunfang ZHANG

Junjie WANG

Huihui AN

Chao MA

Related Institution

State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Clinical Laboratory, the Second Affiliated Hospital of Zunyi Medical University

Department of Cell Biology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University)

⁰